| Year |
Citation |
Score |
| 2023 |
Djaïleb L, Armstrong WR, Thompson D, Gafita A, Farolfi A, Rajagopal A, Grogan TR, Nguyen K, Benz MR, Hotta M, Barbato F, Ceci F, Schwarzenböck SM, Unterrainer M, Zacho HD, ... ... Carroll P, et al. Presurgical Ga-PSMA-11 Positron Emission Tomography for Biochemical Recurrence Risk Assessment: A Follow-up Analysis of a Multicenter Prospective Phase 3 Imaging Trial. European Urology. PMID 37482512 DOI: 10.1016/j.eururo.2023.06.022 |
0.308 |
|
| 2023 |
Langlais CS, Graff RE, Van Blarigan EL, Neuhaus JM, Cowan JE, Broering JM, Carroll P, Kenfield SA, Chan JM. Post-diagnostic health behaviour scores and risk of prostate cancer progression and mortality. British Journal of Cancer. PMID 37217583 DOI: 10.1038/s41416-023-02283-1 |
0.418 |
|
| 2022 |
Carroll P. Gleason Grade 1 Prostate Cancer Volume at Biopsy Is Associated With Upgrading, but Not Adverse Pathology or Recurrence After Radical Prostatectomy: Results From a Large Institutional Cohort. Reply. The Journal of Urology. 209: 73. PMID 36484446 DOI: 10.1097/JU.0000000000002992 |
0.449 |
|
| 2022 |
Beckmann K, Santaolalla A, Sugimoto M, Carroll P, Rubio J, Villers A, Bjartell A, Morgan T, Dasgupta P, Van Hemelrijck M, Elhage O. Risk of progression following a negative biopsy in prostate cancer active surveillance. Prostate Cancer and Prostatic Diseases. PMID 36008540 DOI: 10.1038/s41391-022-00582-x |
0.421 |
|
| 2022 |
Remmers S, Helleman J, Nieboer D, Trock B, Hyndman ME, Moore CM, Gnanapragasam V, Shiong Lee L, Elhage O, Klotz L, Carroll P, Pickles T, Bjartell A, Robert G, Frydenberg M, et al. Active Surveillance for Men Younger than 60 Years or with Intermediate-risk Localized Prostate Cancer. Descriptive Analyses of Clinical Practice in the Movember GAP3 Initiative. European Urology Open Science. 41: 126-133. PMID 35813247 DOI: 10.1016/j.euros.2022.05.012 |
0.413 |
|
| 2022 |
Olivier J, Li W, Nieboer D, Helleman J, Roobol M, Gnanapragasam V, Frydenberg M, Sugimoto M, Carroll P, Morgan TM, Valdagni R, Rubio-Briones J, Robert G, Stricker P, Hayen A, et al. Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium. European Urology Open Science. 35: 59-67. PMID 35024633 DOI: 10.1016/j.euros.2021.11.006 |
0.415 |
|
| 2021 |
Waisman Malaret AJ, Chang P, Newcomb L, Faino A, Zheng Y, Zhu K, McKenney JK, Brooks JD, Dash A, Ellis WJ, Filson CP, Gleave M, Liss M, Martin FM, Morgan T, ... Carroll P, et al. Effect of Diagnostic Biopsy Practice Location on Grade/Volume Reclassification in Active Surveillance for Prostate Cancer: A Multicenter Analysis from the Canary PASS Cohort. Urology Practice. 8: 576-582. PMID 37145399 DOI: 10.1097/UPJ.0000000000000245 |
0.438 |
|
| 2021 |
Beckmann K, Santaolalla A, Helleman J, Carroll P, Ha Chung B, Shiong Lee L, Perry A, Rubio-Briones J, Sugimoto M, Trock B, Valdagni R, Dasgupta P, Van Hemelrijck M, Elhage O. Comparison of Characteristics, Follow-up and Outcomes of Active Surveillance for Prostate Cancer According to Ethnicity in the GAP3 Global Consortium Database. European Urology Open Science. 34: 47-54. PMID 34934967 DOI: 10.1016/j.euros.2021.09.012 |
0.473 |
|
| 2021 |
Waisman Malaret AJ, Chang P, Zhu K, Zheng Y, Newcomb LF, Liu M, McKenney JK, Brooks JD, Carroll P, Dash A, Filson CP, Gleave ME, Liss M, Martin FM, Morgan TM, et al. Evaluating the Outcomes of Active Surveillance in Grade Group 2 Prostate Cancer: Prospective Results From the Canary PASS Cohort. The Journal of Urology. 101097JU000000000000. PMID 34854745 DOI: 10.1097/JU.0000000000002354 |
0.44 |
|
| 2021 |
Vertosick EA, Zappala S, Punnen S, Hugosson J, Boorjian SA, Haese A, Carroll P, Cooperberg M, Bjartell A, Lilja H, Vickers AJ. Individual Patient Data Meta-analysis of Discrimination of the Four Kallikrein Panel Associated With the Inclusion of Prostate Volume. Urology. 157: 102-106. PMID 34450175 DOI: 10.1016/j.urology.2021.08.014 |
0.373 |
|
| 2021 |
Langlais CS, Chan JM, Kenfield SA, Cowan JE, Graff RE, Broering JM, Carroll P, Van Blarigan EL. Post-diagnostic coffee and tea consumption and risk of prostate cancer progression by smoking history. Cancer Causes & Control : Ccc. PMID 33837499 DOI: 10.1007/s10552-021-01417-1 |
0.461 |
|
| 2021 |
Merriel SWD, Moon D, Dundee P, Corcoran N, Carroll P, Partin A, Smith JA, Hamdy F, Moore C, Ost P, Costello T. A modified Delphi study to develop a practical guide for selecting patients with prostate cancer for active surveillance. Bmc Urology. 21: 18. PMID 33541309 DOI: 10.1186/s12894-021-00789-5 |
0.491 |
|
| 2020 |
Cullen J, Lynch JA, Klein EA, Van Den Eeden SK, Carroll P, Mohler JL, Knezevic D, Farrington T, Lu R. Multicenter Comparison of 17-Gene Genomic Prostate Score as a Predictor of Outcomes in Black and White Men with Clinically Localized Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 33493001 DOI: 10.1097/JU.0000000000001484 |
0.474 |
|
| 2020 |
Smith R, Liu M, Liby T, Bayani N, Bucher E, Chiotti K, Derrick D, Chauchereau A, Heiser L, Alumkal J, Feiler H, Carroll P, Korkola JE. Enzalutamide response in a panel of prostate cancer cell lines reveals a role for glucocorticoid receptor in enzalutamide resistant disease. Scientific Reports. 10: 21750. PMID 33303959 DOI: 10.1038/s41598-020-78798-x |
0.367 |
|
| 2020 |
Sachdev S, Carroll P, Sandler H, Nguyen PL, Wafford E, Auffenberg G, Schaeffer E, Roach M, Evans CP, Hussain M. Assessment of Postprostatectomy Radiotherapy as Adjuvant or Salvage Therapy in Patients With Prostate Cancer: A Systematic Review. Jama Oncology. PMID 32852528 DOI: 10.1001/jamaoncol.2020.2832 |
0.428 |
|
| 2019 |
Ten Ham RMT, Broering JM, Cooperberg M, Carroll P, Wilson LS. Understanding the Major Factors Affecting Response Shift Effects on Health-Related Quality of Life: What the Then-Test Measures in a Longitudinal Prostate Cancer Registry. Clinical Genitourinary Cancer. PMID 31796344 DOI: 10.1016/J.Clgc.2019.10.026 |
0.325 |
|
| 2019 |
Weinstock C, Suzman D, Kluetz P, Baxley J, Viviano C, Ibrahim A, Jarow J, Sridhara R, Liu K, Carroll P, Eggener S, Freidlin B, Hu JC, Hussain M, King M, et al. Development of Treatments for Localized Prostate Cancer in Patients Eligible for Active Surveillance: FDA Oncology Center of Excellence Public Workshop. The Journal of Urology. 101097JU000000000000. PMID 31502940 DOI: 10.1097/JU.0000000000000532 |
0.427 |
|
| 2019 |
Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, Cooperberg MR, Carroll P, Chan JM. Obesity at diagnosis and prostate cancer prognosis and recurrence risk following primary treatment by radical prostatectomy. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 31462398 DOI: 10.1158/1055-9965.Epi-19-0488 |
0.358 |
|
| 2019 |
Friedlander TW, Welty C, Anantharaman A, Schonhoft JD, Jendrisak A, Lee J, Li P, Hough J, Stromlund A, Kobayashi Y, Simko J, Farrokhian N, Lindquist K, Greene S, Ontiveros P, ... ... Carroll P, et al. Identification and Characterization of Circulating Tumor Cells in Men Who Have Undergone Prostatectomy for Clinically Localized, High - Risk Prostate Cancer. The Journal of Urology. 101097JU000000000000. PMID 31216253 DOI: 10.1097/Ju.0000000000000393 |
0.421 |
|
| 2019 |
van der Kwast TH, Helleman J, Nieboer D, Bruinsma SM, Roobol MJ, Trock B, Ehdaie B, Carroll P, Filson C, Kim J, Logothetis C, Morgan T, Klotz L, Pickles T, et al. Consistent Biopsy Quality and Gleason Grading Within the Global Active Surveillance Global Action Plan 3 Initiative: A Prerequisite for Future Studies. European Urology Oncology. 2: 333-336. PMID 31200849 DOI: 10.1016/J.Euo.2018.08.017 |
0.44 |
|
| 2018 |
Aggarwal R, Wei X, Kim W, Small EJ, Ryan CJ, Carroll P, Cooperberg M, Evans MJ, Hope T. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer. European Urology Oncology. 1: 78-82. PMID 31100231 DOI: 10.1016/j.euo.2018.03.010 |
0.408 |
|
| 2018 |
McKiernan J, Donovan MJ, Margolis E, Partin A, Carter B, Brown G, Torkler P, Noerholm M, Skog J, Shore N, Andriole G, Thompson I, Carroll P. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy. European Urology. PMID 30237023 DOI: 10.1016/j.eururo.2018.08.019 |
0.459 |
|
| 2017 |
Kim CS, Lee JY, Chung BH, Kim WJ, Fai NC, Hakim L, Umbas R, Ong TA, Lim J, Letran JL, Chiong E, Wu TL, Lojanapiwat B, Türkeri L, Murphy DG, ... ... Carroll P, et al. Report of the Second Asian Prostate Cancer (A-CaP) Study Meeting. Prostate International. 5: 95-103. PMID 28828352 DOI: 10.1016/j.prnil.2017.03.006 |
0.494 |
|
| 2016 |
Villa S, Kendel F, Venderbos L, Rancati T, Bangma C, Carroll P, Denis L, Klotz L, Korfage IJ, Lane AJ, Magnani T, Mastris K, Rannikko A, Roobol M, Trock B, et al. Setting an Agenda for Assessment of Health-related Quality of Life Among Men with Prostate Cancer on Active Surveillance: A Consensus Paper from a European School of Oncology Task Force. European Urology. PMID 27720532 DOI: 10.1016/J.Eururo.2016.09.041 |
0.375 |
|
| 2016 |
Akaza H, Hirao Y, Kim CS, Oya M, Ozono S, Ye D, Cooperberg M, Hinotsu S, Lee JY, Zhu G, Namiki M, Horie S, Chung BH, Chen CH, Fai NC, ... ... Carroll P, et al. Asia prostate cancer study (A-CaP Study) launch symposium. Prostate International. 4: 88-96. PMID 27689065 DOI: 10.1016/J.Prnil.2016.03.001 |
0.433 |
|
| 2016 |
Crawford ED, Rosenberg MT, Partin AW, Cooperberg MR, Maccini M, Loeb S, Pettaway CA, Shore ND, Arangua P, Hoenemeyer J, Leveridge M, Leapman M, Pinto P, Thompson I, Carroll P, et al. An Approach Using PSA Levels of 1.5 ng/ml as the Cutoff for Prostate Cancer Screening in Primary Care. Urology. PMID 27450937 DOI: 10.1016/j.urology.2016.07.001 |
0.374 |
|
| 2016 |
Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, Briganti A, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, et al. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. European Urology. PMID 27349615 DOI: 10.1016/j.eururo.2016.06.011 |
0.424 |
|
| 2016 |
McKiernan J, Donovan MJ, O'Neill V, Bentink S, Noerholm M, Belzer S, Skog J, Kattan MW, Partin A, Andriole G, Brown G, Wei JT, Thompson IM, Carroll P. A Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer at Initial Biopsy. Jama Oncology. PMID 27032035 DOI: 10.1001/Jamaoncol.2016.0097 |
0.447 |
|
| 2015 |
Carlsson S, Leapman M, Carroll P, Schröder F, Albertsen PC, Ilic D, Barry M, Frosch DL, Vickers A. Who and when should we screen for prostate cancer? Interviews with key opinion leaders. Bmc Medicine. 13: 288. PMID 26612204 DOI: 10.1186/s12916-015-0526-x |
0.457 |
|
| 2015 |
Dall'Era M, Carroll P. What is the Optimal Way to Select Candidates for Active Surveillance of Prostate Cancer? The Journal of Urology. 194: 615-6. PMID 26079332 DOI: 10.1016/j.juro.2015.06.069 |
0.435 |
|
| 2014 |
Akaza H, Kim CS, Carroll P, Choi IY, Chung BH, Cooperberg MR, Hirao Y, Hinotsu S, Horie S, Lee JY, Namiki M, Ng CF, Onozawa M, Ozono S, Ueno S, et al. Seventh Joint Meeting of K-J-CaP and CaPSURE: extending the global initiative to improve prostate cancer management. Prostate International. 2: 50-69. PMID 26153555 DOI: 10.12954/Pi.14047 |
0.48 |
|
| 2014 |
Fong L, Carroll P, Weinberg V, Chan S, Lewis J, Corman J, Amling CL, Stephenson RA, Simko J, Sheikh NA, Sims RB, Frohlich MW, Small EJ. Activated lymphocyte recruitment into the tumor microenvironment following preoperative sipuleucel-T for localized prostate cancer. Journal of the National Cancer Institute. 106. PMID 25255802 DOI: 10.1093/jnci/dju268 |
0.413 |
|
| 2014 |
Jarow JP, Thompson IM, Kluetz PG, Baxley J, Sridhara R, Scardino P, Carroll P, Albertsen P, Carter HB, Brawley O, Sartor O, Sandler H, Kiefert JJ, Morton RA. Drug and device development for localized prostate cancer: report of a Food and Drug Administration/American Urological Association public workshop. Urology. 83: 975-8. PMID 24661332 DOI: 10.1016/j.urology.2013.10.087 |
0.436 |
|
| 2014 |
Loeb S, Bjurlin MA, Nicholson J, Tammela TL, Penson DF, Carter HB, Carroll P, Etzioni R. Overdiagnosis and overtreatment of prostate cancer. European Urology. 65: 1046-55. PMID 24439788 DOI: 10.1016/J.Eururo.2013.12.062 |
0.478 |
|
| 2014 |
Pfister D, Bolla M, Briganti A, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early salvage radiotherapy following radical prostatectomy. European Urology. 65: 1034-43. PMID 23972524 DOI: 10.1016/j.eururo.2013.08.013 |
0.381 |
|
| 2013 |
Akaza H, Hinotsu S, Cooperberg MR, Chung BH, Youl Lee J, Umbas R, Tsukamoto T, Namiki M, Carroll P. Sixth joint meeting of J-CaP and CaPSURE--a multinational perspective on prostate cancer management and patient outcomes. Japanese Journal of Clinical Oncology. 43: 756-66. PMID 23723314 DOI: 10.1093/jjco/hyt071 |
0.491 |
|
| 2013 |
Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. The Journal of Urology. 189: S2-S11. PMID 23234625 DOI: 10.1016/j.juro.2012.11.014 |
0.429 |
|
| 2012 |
Hayes GM, Simko J, Holochwost D, Kuchinsky K, Busch R, Misell L, Murphy EJ, Carroll P, Chan J, Shinohara K, Hellerstein MK. Regional cell proliferation in microdissected human prostate specimens after heavy water labeling in vivo: correlation with prostate epithelial cells isolated from seminal fluid. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3250-60. PMID 22553345 DOI: 10.1158/1078-0432.Ccr-11-2988 |
0.464 |
|
| 2012 |
Akaza H, Carroll P, Cooperberg MR, Hinotsu S. Fifth Joint Meeting of J-CaP and CaPSURE: advancing the global understanding of prostate cancer and its management. Japanese Journal of Clinical Oncology. 42: 226-36. PMID 22217576 DOI: 10.1093/jjco/hyr194 |
0.47 |
|
| 2011 |
Kazer MW, Bailey DE, Colberg J, Kelly WK, Carroll P. The needs for men undergoing active surveillance (AS) for prostate cancer: results of a focus group study. Journal of Clinical Nursing. 20: 581-6. PMID 21219530 DOI: 10.1111/J.1365-2702.2010.03489.X |
0.468 |
|
| 2011 |
Moltzahn F, Olshen AB, Baehner L, Peek A, Fong L, Stöppler H, Simko J, Hilton JF, Carroll P, Blelloch R. Microfluidic-based multiplex qRT-PCR identifies diagnostic and prognostic microRNA signatures in the sera of prostate cancer patients. Cancer Research. 71: 550-60. PMID 21098088 DOI: 10.1158/0008-5472.CAN-10-1229 |
0.386 |
|
| 2010 |
Paris PL, Weinberg V, Albo G, Roy R, Burke C, Simko J, Carroll P, Collins C. A group of genome-based biomarkers that add to a Kattan nomogram for predicting progression in men with high-risk prostate cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 16: 195-202. PMID 20028763 DOI: 10.1158/1078-0432.CCR-09-0948 |
0.41 |
|
| 2010 |
Aaronson D, Cowan J, Carroll P, Konety B. Association of age and response to androgen-deprivation therapy with or without radiotherapy for prostate cancer: data from CaPSURE. Bju International. 105: 951-5. PMID 19889066 DOI: 10.1111/j.1464-410X.2009.08886.x |
0.341 |
|
| 2009 |
Greene KL, Albertsen PC, Babaian RJ, Carter HB, Gann PH, Han M, Kuban DA, Sartor AO, Stanford JL, Zietman A, Carroll P. Prostate specific antigen best practice statement: 2009 update. The Journal of Urology. 182: 2232-41. PMID 19781717 DOI: 10.1016/j.juro.2009.07.093 |
0.429 |
|
| 2008 |
Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV. Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality. Urology. 71: 136-40. PMID 18242382 DOI: 10.1016/J.Urology.2007.08.028 |
0.43 |
|
| 2008 |
Kurhanewicz J, Vigneron D, Carroll P, Coakley F. Multiparametric magnetic resonance imaging in prostate cancer: Present and future Current Opinion in Urology. 18: 71-77. PMID 18090494 DOI: 10.1097/Mou.0B013E3282F19D01 |
0.333 |
|
| 2007 |
Alexander BM, Chen M, Carroll P, D'Amico aAV. Prostate-Specific Antigen Level at Initiation of Hormonal Therapy After Prostate-Specific Antigen Failure Following Prostatectomy or Radiotherapy and Therapeutic Response Urology. 70: 320-323. PMID 17826497 DOI: 10.1016/J.Urology.2007.03.074 |
0.402 |
|
| 2006 |
Ryan CJ, Elkin EP, Small EJ, Duchane J, Carroll P. Reduced incidence of bony metastasis at initial prostate cancer diagnosis: Data from CaPSURE™ Urologic Oncology: Seminars and Original Investigations. 24: 396-402. PMID 16962488 DOI: 10.1016/j.urolonc.2005.09.003 |
0.387 |
|
| 2006 |
Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C, Gao B, Carroll P, Ornish D. Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance Urology. 67: 125-130. PMID 16413347 DOI: 10.1016/j.urology.2005.07.056 |
0.338 |
|
| 2005 |
Langenstroer P, Carroll P, Thrasher JB. Clinical and pathological characteristics of unstageable prostate cancer: analysis of the CaPSURE database. The Journal of Urology. 174: 118-20. PMID 15947594 DOI: 10.1097/01.ju.0000162038.62740.9f |
0.437 |
|
| 2005 |
Zhao H, Shiina H, Greene KL, Li LC, Tanaka Y, Kishi H, Igawa M, Kane CJ, Carroll P, Dahiya R. CpG methylation at promoter site -140 inactivates TGFbeta2 receptor gene in prostate cancer. Cancer. 104: 44-52. PMID 15895377 DOI: 10.1002/cncr.21135 |
0.329 |
|
| 2004 |
Watson JEV, Kamkar S, James K, Kowbel D, Andaya A, Paris PL, Simko J, Carroll P, McAlhany S, Rowley D, Collins C. Molecular analysis of WFDC1/ps20 gene in prostate cancer Prostate. 61: 192-199. PMID 15305342 DOI: 10.1002/pros.20100 |
0.414 |
|
| 2003 |
Patra SK, Patra A, Zhao H, Carroll P, Dahiya R. Methyl-CpG-DNA binding proteins in human prostate cancer: expression of CXXC sequence containing MBD1 and repression of MBD2 and MeCP2. Biochemical and Biophysical Research Communications. 302: 759-66. PMID 12646234 DOI: 10.1016/s0006-291x(03)00253-5 |
0.367 |
|
| 2003 |
Paris PL, Albertson DG, Alers JC, Andaya A, Carroll P, Fridlyand J, Jain AN, Kamkar S, Kowbel D, Krijtenburg PJ, Pinkel D, Schröder FH, Vissers KJ, Watson VJ, Wildhagen MF, et al. High-resolution analysis of paraffin-embedded and formalin-fixed prostate tumors using comparative genomic hybridization to genomic microarrays. The American Journal of Pathology. 162: 763-70. PMID 12598311 DOI: 10.1016/S0002-9440(10)63873-4 |
0.378 |
|
| Show low-probability matches. |